<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-alpha, a potent stimulus of nuclear factor-kappaB (NF-kappaB), is up-regulated in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we show that bone marrow mononuclear cells (BMMCs) and purified CD34+ cells from patients with low-grade/early-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo>/<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts [RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>]) have low levels of NF-kappaB activity in nuclear extracts comparable with <z:mpath ids='MPATH_458'>normal</z:mpath> marrow, while patients with RA with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) show significantly increased levels of activity (P = .008) </plain></SENT>
<SENT sid="2" pm="."><plain>Exogenous TNF-alpha enhanced NF-kappaB nuclear translocation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> BMMCs above baseline levels </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> (ATO; 2-200 microM) inhibited NF-kappaB activity in <z:mpath ids='MPATH_458'>normal</z:mpath> marrow, primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and ML1 cells, even in the presence of exogenous TNF-alpha (20 ng/mL), and down-regulated NF-kappaB-dependent antiapoptotic proteins, B-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> XL (Bcl-XL), Bcl-2, <z:hpo ids='HP_0001417'>X-linked</z:hpo> inhibitor of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (XIAP), and Fas-associated <z:hpo ids='HP_0011420'>death</z:hpo> domain (FADD)-like interleukin-1beta-converting enzyme (FLICE) inhibitory protein (FLIP), leading to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>However, overexpression of FLIP resulted in increased NF-kappaB activity and rendered ML1 cells resistant to ATO-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>These data are consistent with the observed up-regulation of FLIP and resistance to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, where ATO as a single agent may show only limited efficacy </plain></SENT>
<SENT sid="6" pm="."><plain>However, the data also suggest that combinations of ATO with agents that interfere with other pathways, such as FLIP autoamplification via NF-kappaB, may have considerable therapeutic activity </plain></SENT>
</text></document>